ESALY - Eisai C2N team up to build real-world evidence for blood-based tests for cognitive disorders

• Eisai ( OTCPK:ESALY ) ( OTCPK:ESALF ) and C2N Diagnostics entered a memorandum of understanding that will seek to build awareness about how blood-based assays for cognitive impairment, including Alzheimer's disease (AD), may help patients receive a timely diagnosis especially in traditionally underserved communities.
• The company said they will develop real-world evidence to support the use of blood-based assays in people living with cognitive impairment who are not currently participating in a clinical trial.
• The development and adoption of blood-based assays in everyday clinical practice is important in improving care for people in remote and underserved communities where access to traditional diagnostic tools of positron emission tomography (PET) and lumbar punctures are not a viable option, the company said in an Aug. 23 press release.

For further details see: